Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.26M$5.26Mderived+16.8% vs Q4 2015 Net Income-$3.43M-$3.43MderivedN/M vs Q4 2015 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,745,626+1,153.5% Operating Incomederived-$3,064,687N/M Operating Cash Flowderived$1,473,993−45.4% Free Cash Flowderived$1,366,939−32.1% Margins · derivedGross margin33.2%+30.1 pt vs Q4 2015
Operating margin-58.2%+162.2 pt vs Q4 2015
Net margin-65.1%+276.8 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 31, 2017 · 90 d after period end